Novel oral anticoagulants, with dabigatran in particular have failed in their quest to replace the traditional anticoagulation in the form of vitamin K antagonist in patients with mechanical valvular implants. However, the same had not been tried in bioprosthetic valve recipients until recently in a large trial where rivaroxaban was found to be non-inferior to warfarin on head-to-head basis. This commentary discusses the various aspects related to oral anticoagulation in bioprosthetic valve recipients in the light of recent clinical evidence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424354 | PMC |
| http://dx.doi.org/10.1016/j.ihj.2021.06.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heart Transplantation Outcomes for Fontan Patients When Using Contemporary Strategies: Heart-Liver Transplantation and Ventricular Assist Device Therapy.
World J Pediatr Congenit Heart Surg
January 2025
The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Background: With an increasing number of Fontan patients surviving into adulthood, the burden of end-stage heart failure is increasing. Prior studies have reported suboptimal heart transplantation (HTx) outcomes. Therefore, the authors describe their institutional experience of HTx in patients with Fontan circulation failure, including heart-liver transplantation (HLTx) and pretransplant systemic ventricular assist device (SVAD) therapies.
View Article and Find Full Text PDFFate of Semilunar Valves From Discarded Hearts at the Time of Pediatric Heart Retransplantation.
Pediatr Transplant
February 2025
The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Background: Partial heart transplantation (PHT) is a novel procedure for children in need of a growing valve replacement option. One challenge is identifying suitable donor valves. Semilunar heart valves from patients receiving a retransplant may be a source, however their functionality and growth potential especially at the time of retransplant are unknown.
View Article and Find Full Text PDFComparison of Long-Term Performance of Porcine versus Pericardial Bioprostheses.
Thorac Cardiovasc Surg
January 2025
Cardiothoracic surgery, CHU de Rennes, Rennes, France.
Background: The long-term comparative results between porcine and pericardial bioprostheses for surgical aortic valve replacement (SAVR) is debated. Scarce information exists concerning direct comparative evaluation among contemporary devices. We compared late and very late results in a single center series (N=3,983 cases).
View Article and Find Full Text PDFDomino partial heart transplantation.
Am J Transplant
December 2024
Department of Cardiovascular Surgery, Arkansas Children's Hospital, Little Rock, Arkansas, USA. Electronic address:
Heart valve replacement in pediatric cardiothoracic surgery poses problems because conventional heart valve implants do not have the ability to grow. This mandates serial reoperations for implant exchanges until an adult-size implant can fit. Partial heart transplantation eliminates these reoperations because the transplanted valves grow.
View Article and Find Full Text PDFProspective validation of a prespecified algorithm for the management of conduction disturbances after transcatheter aortic valve replacement: The PROMOTE study.
Heart Rhythm
December 2024
Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.
Background: There is a large variability in the management of conduction disturbances (CDs) after transcatheter aortic valve replacement (TAVR).
Objective: This study aimed to validate a prespecified algorithm for managing CDs in patients undergoing TAVR.
Methods: This was a prospective multicenter study including consecutive patients without prior pacemaker undergoing TAVR.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!